Pfizer (PFE) DIvidends Date & History

Key Takeaways

• Pfizer Inc. (PFE) offers a current dividend yield of 6.22% with an annual payout of $1.72 per share.
• The company pays dividends quarterly and has raised its dividend for 15 consecutive years.
• Free cash flow provides solid coverage of the dividend at approximately 89%.
• The dividend payout ratio on an earnings basis exceeds 200% in recent periods due to accounting factors.
• Pfizer Inc. (PFE) yield significantly exceeds the average for large pharmaceutical peers.
• The stock appeals to income-focused investors seeking reliable quarterly distributions.

Dividend Overview

Pfizer Inc. (PFE) maintains a quarterly dividend payment schedule, distributing $0.43 per share four times a year for an annualized total of $1.72. At the recent share price near $27.66, this translates to a trailing twelve-month yield of 6.22%. The company follows a consistent policy of returning capital to shareholders through dividends, positioning it as a high-yield stock within the pharmaceutical sector rather than a rapid dividend growth name. Payments occur on a regular quarterly cadence, with the most recent ex-dividend date falling on July 24, 2026, and the corresponding payment on September 1, 2026. This profile suits investors prioritizing current income over aggressive growth in distributions.

Dividend History and Growth

Pfizer Inc. (PFE) has delivered dividends without interruption for decades and extended its streak of annual increases to 15 consecutive years. The quarterly rate rose modestly from $0.42 in 2024 to $0.43 in 2025 and has remained steady through 2026. Earlier years showed gradual step-ups, such as from $0.40 in 2022 to $0.41 in 2023. This pattern reflects a conservative approach to dividend growth, prioritizing sustainability amid fluctuating earnings from product cycles and acquisitions. The long payment history underscores management commitment to shareholder returns even during periods of revenue pressure from patent expirations.

Dividend Sustainability and Payout Ratio

Dividend sustainability appears supported by free cash flow despite an elevated earnings payout ratio exceeding 200% in recent reports. Trailing twelve-month free cash flow of approximately $11 billion covers the roughly $9.8 billion annual dividend outlay at about 89%. Recent impairments and accounting charges have inflated the earnings-based ratio, yet cash generation remains adequate. Pfizer Inc. (PFE) maintains a manageable debt load relative to its cash position, providing additional flexibility. Management has reaffirmed commitment to the dividend, indicating no near-term cuts are anticipated provided cash flows stabilize.

Dividend Compared to Industry Peers

Pfizer Inc. (PFE) dividend yield of 6.22% stands well above most large-cap pharmaceutical peers. Johnson & Johnson (JNJ) yields 1.94%, Merck (MRK) 2.29%, Bristol-Myers Squibb (BMY) 3.98%, and Novartis (NVS) 3.40%. While peers often feature lower yields paired with stronger earnings growth profiles, Pfizer Inc. (PFE) offers superior current income. This relative premium reflects market pricing of near-term challenges such as product patent cliffs, yet the elevated yield may attract income-oriented investors comparing options within the healthcare sector.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify dividend stocks, income-focused investments, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore opportunities with the AI Screener today.

Is This Stock Attractive for Dividend Investors?

Pfizer Inc. (PFE) may suit income investors seeking above-average yields and a proven record of quarterly payments. Conservative dividend investors could value the 15-year growth streak and free cash flow coverage, though the elevated earnings payout ratio warrants monitoring of future cash generation. Long-term holders focused on total return might appreciate the discounted valuation alongside the dividend, while those prioritizing rapid dividend increases may find the modest recent growth less compelling. Dividend growth investors could view the stock as a stable income component rather than a primary growth holding. Overall suitability depends on individual portfolio needs for current yield versus capital appreciation potential in the pharmaceutical industry.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations